Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial and parasitic deoxyribonucleic acid (DNA) serves as the essential repository of genetic information required for the survival, growth, and reproduction of pathogenic microorganisms. In bacteria, this typically consists of a single circular chromosome and various plasmids, while in parasites, it encompasses complex nuclear and sometimes kinetoplast DNA. This molecule is a primary therapeutic target for the nitroimidazole and nitrofuran classes of antimicrobials, which are particularly effective against anaerobic bacteria and certain protozoa. These drugs are selectively activated within the low-redox environment of the pathogen to form reactive radicals that cause catastrophic structural damage to the DNA, such as strand breakage and helix destabilization (StatPearls, 2023). This direct chemical attack prevents the pathogen from replicating its genome or transcribing essential genes, leading to rapid cell death. Because the activation of these drugs requires specific microbial metabolic pathways not present in aerobic human cells, the target offers a degree of selective toxicity (PubMed, PMID: 15833283). Clinical applications include the treatment of infections caused by Bacteroides species, Clostridioides difficile, and parasites like Trichomonas vaginalis and Giardia lamblia.
Drugs such as nitroimidazoles and nitrofurans act as prodrugs that undergo reductive activation by microbial enzymes (e.g., pyruvate:ferredoxin oxidoreductase) in anaerobic or microaerophilic environments. This reduction generates highly reactive nitro-radical anions and other short-lived reactive intermediates that cause direct oxidative damage to the DNA molecule. This damage includes the induction of single- and double-strand breaks, destabilization of the DNA helix, and covalent binding to the nucleic acid, which collectively inhibit DNA synthesis and lead to microbial cell death (StatPearls, 2023; PubMed, PMID: 15833283).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial and parasitic deoxyribonucleic acid (DNA).